PM
Parabilis Medicines
United States · Biotech
Develops medicines targeting historically undruggable protein targets in cancer
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series F | $305M | Alderline Group — Role not disclosedARCH Venture Partners — Role not disclosedCatalio Capital Management — Role not disclosedCormorant Asset Management — Role not disclosedFarallon Capital Management — Role not disclosedFidelity Management & Research Company — Role not disclosedForesite Capital — Role not disclosedFrazier Life Sciences — Role not disclosedGeneral Catalyst — Role not disclosedGV (Google Ventures) — Role not disclosedHBM Healthcare — Role not disclosedInvus — Role not disclosedJanus Henderson Investors — Role not disclosedMarshall Wace — Role not disclosedMilky Way Investments — Role not disclosedNextech Invest — Role not disclosedRA Capital Management — Role not disclosedRock Springs Capital — Role not disclosedSamsara BioCapital — Role not disclosedSixty Degree Capital — Role not disclosedSoleus Capital — Role not disclosedT. Rowe Price Associates — Role not disclosedvenBio Partners — Role not disclosed |